Home Newsfeeds Credit Suisse Maintains Neutral on Affirm Holdings, Lowers Price Target to $21

Credit Suisse Maintains Neutral on Affirm Holdings, Lowers Price Target to $21

Credit Suisse analyst Timothy Chiodo maintains Affirm Holdings (NASDAQ:AFRM) with a Neutral and lowers the price target from $27 to $21.

byBenzinga Newsdesk

November 9, 2022

1 minute read

Credit Suisse analyst Timothy Chiodo maintains Affirm Holdings (NASDAQ:AFRM) with a Neutral and lowers the price target from $27 to $21.

$10 Million Bet On Dyne Therapeutics? Check Out These 4 Stocks Insiders Are Buying

By Lisa Levin

December 15, 10:15 AM

Although US stocks closed lower on Wednesday following Fed’s rate decision, there were a few notable insider trades.

DYN

Wall Street Wobbles: Stock Futures Point To Slide As JPMorgan Tumbles 3% While Gold Surges Past $2,400 — Analyst Sees This As ‘Worst-Case’ Scenario For S&P 500 Pullback

By Shanthi Rexaline

April 12, 7:27 AM

The relief rally sparked by Thursday’s producer price index report is teetering on the edge.

AMD

AIM ImmunoTech Enrolls And Doses First Subject In Phase 2 Study Evaluating Ampligen For The Treatment Of Post-COVID Conditions

By Happy Mohamed

July 10, 8:13 AM

Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in Q4 2023 OCALA, Fla., July 10, 2023 (GLOBE NEWSWIRE)

AIM

Will Apple Crack AI Code And Spark Investor Optimism? Tim Cook’s Tech Strategy In Focus Amid Expected Q2 Slump

By Shanthi Rexaline

May 2, 8:19 AM

The rough patch could continue for Apple, reflecting economic shakiness, which could hit its consumer-focused products.

AAPL

Credit Suisse Maintains Neutral on Affirm Holdings, Lowers Price Target to $21

Related Posts

$10 Million Bet On Dyne Therapeutics? Check Out These 4 Stocks Insiders Are Buying

Wall Street Wobbles: Stock Futures Point To Slide As JPMorgan Tumbles 3% While Gold Surges Past $2,400 — Analyst Sees This As ‘Worst-Case’ Scenario For S&P 500 Pullback

AIM ImmunoTech Enrolls And Doses First Subject In Phase 2 Study Evaluating Ampligen For The Treatment Of Post-COVID Conditions

Will Apple Crack AI Code And Spark Investor Optimism? Tim Cook’s Tech Strategy In Focus Amid Expected Q2 Slump